The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Torii's Japan sales performance.
Kyowa Kirin has been selling Poteligeo in Japan since 2012, and the company says its approval in the US is a key milestone on the path to becoming a global specialty ... Sales of Poteligeo in Japan were 1.9bn yen ($17m) in fiscal 2017, and are
Overall sales fell 5% to $10.33bn, however, thanks to generic competition taking another chunk out of cholesterol drug Crestor (rosuvastatin) sales, particularly in Europe and Japan. ... its launch in Japan, while Tagrisso grew 82% to $760m on the back
This still leaves it in line with an unweighted EU-15 average of 9.8% of national income, but far behind countries such as the US (16.9%), Japan (11.2%),
is already on the market in Japan, where its originator Shionogi won approval earlier this year as Xofluza.
This still leaves it in line with an unweighted EU-15 average of 9.8% of national income, but far behind countries such as the US (16.9%), Japan (11.2%),
[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...